Orris

Tell me how to treat tardive dyskinesia

Reading File
Finding Sources
Finding Sources
Searching PubMed

"tardive dyskinesia" AND treatment

Searching the Web

tardive dyskinesia treatment VMAT2 inhibitors guideline APA 2025

Reading File
Reading File
Reading File
Reading Article

PMID: 41981317

Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC13064733

Treatment should be directed by a psychiatrist or neurologist, because tardive dyskinesia (TD) can persist and changing the causal drug abruptly may temporarily worsen movements.
  1. Confirm the diagnosis and assess severity
    • Review all dopamine-blocking medicines, especially antipsychotics and metoclopramide.
    • Document severity and impact with a structured scale such as AIMS, including effects on speech, eating, breathing, walking, pain, and distress.
    • Exclude mimics such as Huntington disease, Wilson disease, thyroid/parathyroid disorders, or other medication-related dyskinesias. TD commonly causes lip smacking, tongue movements, facial grimacing, and irregular limb or trunk movements. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, p. 9235.
  2. Use a VMAT2 inhibitor when TD is clinically significant
    • Valbenazine and deutetrabenazine are the main evidence-supported, FDA-approved treatments in the United States. They may be used while the person continues necessary antipsychotic treatment.
    • Choice depends on comorbid depression or suicidality, sedation risk, QT-risk factors, liver function, interacting medications, dosing preference, coverage, and clinician experience.
    • Monitor for sleepiness, parkinsonism, mood changes, akathisia, and drug interactions. Review the full prescribing information before prescribing.
    • A recent systematic review and network meta-analysis found the clearest randomized-trial signal for valbenazine, but judged much of the comparative evidence low certainty and reported psychiatric adverse events in some trials (2026 systematic review, PMID 41981317).
  3. Reassess the offending medicine, but do not stop it on your own
    • If clinically safe, the prescriber may lower the dose, stop the dopamine-blocking drug, or substitute a lower-TD-risk treatment.
    • This must be balanced against relapse of psychosis, mania, nausea, or other condition for which the medicine is being used.
    • Reducing or stopping an antipsychotic can produce temporary worsening or unmasking of movements, called withdrawal-emergent dyskinesia. Raising an antipsychotic dose merely to suppress movements is generally not a durable strategy. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, p. 9235.
  4. Avoid common mistakes
    • Anticholinergic drugs such as benztropine or trihexyphenidyl generally worsen TD. They can help drug-induced parkinsonism or acute dystonia, which are different problems, so medication changes require careful diagnosis. The Clozapine Handbook, p. 155.
    • Older or less-supported options such as vitamin E, benzodiazepines, amantadine, or supplements should not replace a VMAT2 inhibitor without specialist guidance. Evidence for many historical treatments is limited.
  5. If antipsychotic treatment must continue
    • Treat TD directly with a VMAT2 inhibitor rather than automatically switching to clozapine.
    • Clozapine may be appropriate for some psychiatric indications, but switching solely to treat TD is not the routine evidence-based approach. Do not discontinue clozapine solely because TD appears, since doing so can risk psychiatric relapse; specialist review is appropriate. The Clozapine Handbook, p. 154-155.
  6. Support and follow-up
    • Review response, adverse effects, mood, function, and AIMS score regularly.
    • Speech, swallowing, dental, occupational, and physical therapy can help when movements impair daily functioning.
    • Seek urgent medical assessment for difficulty breathing or swallowing, severe tongue/jaw injury, falls, inability to eat or drink, or suicidal thoughts.
Symptoms often return when a VMAT2 inhibitor is stopped, so treatment is usually ongoing if it remains beneficial. Current guidance supports valbenazine or deutetrabenazine as first-line pharmacologic options, as summarized by the American Association of Psychiatric Pharmacists.
This is a shared conversation. Sign in to Orris to start your own chat.